1608.0000 -16.50 (-1.02%)
NSE Aug 20, 2026 15:31 PM
Volume: 805.9K
 

1608.00
-1.02%
ICICI Direct
Q2FY26- Muted numbers on expected lines Revenues grew ~6% YoY to 8286 crore due to softness in the US (44% of the revenues) which grew 3% to 3638 crore. Europe (30% of the revenues) grew 18% to 2480 crore and ARV (~4% of the revenues) grew 68% to 325 crore. Growth Markets (~10% of the revenues) grew ~9% YoY to 882 crore (including India formulations). APIs de-grew at 17% YoY to 961 crores. EBITDA grew 7% YoY to 1678 crore while EBITDA margins increased 16 bps to 20.3%. EBITDA de-growth was mainly driven by increase in employee expenses....
Deven Choksey increased Accumulate price target of Aurobindo Pharma Ltd. to 1758.0 on 07 Aug, 2026.
More from Aurobindo Pharma Ltd.
Recommended